

**Central Memory CD8<sup>+</sup> T Cells  
Appear to Have a Shorter Lifespan  
and Reduced Abundance As a  
Function of HIV Disease  
Progression**

**A Collaboration between J. “Mike” McCune’s  
& Marc K. Hellerstein’s Laboratories**

**Universities of California San Francisco &  
Berkeley, California, USA**

**Kristin Ladell**

**Cardiff University, UK**


# Immunodeficiency in HIV Infection

- **Quantitative loss of CD4<sup>+</sup> T cells**
- **Qualitative changes in cell populations that persist**  
Grossman Z et al. *Nat Med* (2006)  
McCune JM. *Cell* (1991)
- **Loss of recall, or “memory”, responses to antigen**  
Clerici M et al. *J Clin Invest* (1989)
- **Loss of polyfunctional CD8<sup>+</sup> “memory” T cells that are able to control HIV viral load**  
Betts MR et al. *Blood* (2006)
- **Such memory responses represent the bedrock upon which the adaptive immune system is based**  
Kaech SM et al. *Nat Immunol.* (2003)  
Schluns KS & Lefrancois L. *Nat Rev Immunol* (2003)  
Seder RA & Ahmed R. *Nat Immunol* (2003)  
Tough DF & Sprent J. *Stem Cells* (1995)

# “Memory” in the T Cell Lineage and Generation and Maintenance of Memory CD8<sup>+</sup> T Cells


- Memory T cells are thought to differentiate from naïve T cells after exposure to antigen
- .. persist for very long periods of time
- .. rapidly proliferate and differentiate into effector T cells after secondary contact with cognate antigen
- Requirements for generation and maintenance of memory CD8<sup>+</sup> T cells include:
  - CD4<sup>+</sup> T cell help
  - a cellular machinery that provides for either self-renewal (e.g., through arrested development mediated by transcriptional repressors) or for limited homeostatic proliferation (e.g. mediated by IL-7 through the IL-7R $\alpha$ ).

# Linear Differentiation or Post-thymic CD8<sup>+</sup> T Cell Development\*



Lanzavecchia A & Sallusto F. Nat Rev Immunol (2002)  
 Champagne P et al. Nature (2001)

CD45RA <sup>+</sup>	<b>CD45RA<sup>-</sup></b>	CD45RA <sup>-(+)</sup>	CD45RA <sup>-(+)</sup>	<b>CD45RA<sup>+/-</sup></b>	<b>CD45RA<sup>+(-)</sup></b>
CCR7 <sup>+</sup>	CCR7 <sup>+</sup>	<b>CCR7<sup>-</sup></b>	CCR7 <sup>-</sup>	CCR7 <sup>-</sup>	CCR7 <sup>-</sup>
CD28 <sup>+</sup>	CD28 <sup>+</sup>	CD28 <sup>+</sup>	<b>CD28<sup>-</sup></b>	CD28 <sup>-</sup>	CD28 <sup>-</sup>
CD27 <sup>+</sup>	CD27 <sup>+</sup>	CD27 <sup>+</sup>	CD27 <sup>+</sup>	<b>CD27<sup>-</sup></b>	CD27 <sup>-</sup>
CD57 <sup>-</sup>	CD57 <sup>-</sup>	CD57 <sup>-</sup>	CD57 <sup>-(+)</sup>	CD57 <sup>-(+)</sup>	<b>CD57<sup>+(-)</sup></b>



\* Appay V & Rowland-Jones SL. Sem Immunol (2004)

***In vivo*  $^2\text{H}_2\text{O}$  or  $^2\text{H}$ -glucose Labelling showed that Higher Proportions of T Cells Are Short-lived in Advanced HIV Infection Compared to Healthy Controls**

- These short-lived cells have a memory/effector phenotype
- Long-lived potential progenitor T cells may be reduced in advanced HIV infection

Hellerstein MK et al. J Clin Invest (2003)


# **These Findings Led Us to Ask the Following Questions:**

- **What is the phenotype and the lifespan of long-lived memory CD8<sup>+</sup> T cells in HIV-negative subjects?**
- **Does this phenotype and/or its lifespan change in the context of progressive HIV disease?**

## **We also Wanted..**

**.. to evaluate the applicability of the stable isotope ( $^2\text{H}_2\text{O}$ ) / FACS / mass spectrometric method for the analysis of low abundance T cell subpopulations**

# Stable Isotope *In Vivo* Labelling with $^2\text{H}_2\text{O}$



# Calculations of Decay Constants, Half-lives, and Percentages of CD8<sup>+</sup> T Cell Subpopulations Remaining after 7 Weeks of <sup>2</sup>H<sub>2</sub>O Labelling

- Loss of label from cellular DNA of each subset was quantified between S2 (week 10) and S4 (week 18)
- The decay constant (k) was calculated using the equation for exponential decay:

$$k = -[\ln(S2/S4)]/Dt$$

- The half-life was calculated as:

$$t_{1/2} = \ln(2)/k$$

- Some CD8<sup>+</sup> T cell subpopulations did not lose label exponentially, which is why we also calculated the percentage of initially incorporated label:

$$[S4/S2]$$

# Phenotypes of Sorted CD3<sup>+</sup>CD8<sup>+</sup> T Cell Subpopulations

## MEMORY & EFFECTOR

T<sub>CM</sub>

- CD45RA<sup>-</sup>CD28<sup>+</sup>CCR7<sup>+</sup>

T<sub>EM1</sub>

- CD45RA<sup>-</sup>CCR7<sup>-</sup> (CD28<sup>+/-</sup>)

T<sub>EM2</sub>

- CD45RA<sup>-</sup>CD28<sup>-</sup>CCR7<sup>-</sup>

## NAÏVE & “RA” EFFECTOR

T<sub>N</sub>

- CD45RA<sup>high</sup>CD28<sup>+</sup>CCR7<sup>+</sup>

T<sub>EMRA</sub>

- CD45RA<sup>high</sup>CD28<sup>-</sup>CCR7<sup>-</sup>

# Characteristics of Study Subjects

Group	Subject ID	Age	VL (copies/ml)	Years HIV-infected	CD4 count / ul of blood	CD8 count / ul of blood	Weeks of <sup>2</sup> H <sub>2</sub> O labeling
HIV-negative	A	27	Negative	-	586	376	7
	B	56	Negative	-	513	292	7
	C	59	Negative	-	555	488	7
	D	64	Negative	-	903	258	7
	E	35	Negative	-	1289	563	ND
	F	35	Negative	-	832	246	ND
HIV-infected (untreated)	L	41	< 75	5	1028	998	ND
	M	40	8278	9	973	1500	ND
	G	40	2,059	NA	852	3388	7
	N	52	713	5	784	1052	ND
	O	52	< 75	17	730	929	ND
	P	52	8469	16	657	1960	ND
	Q	52	< 75	11	642	1067	ND
	R	59	87	15	615	1143	ND
	S	38	392	13	594	2079	ND
	H	41	2,220	NA	532	1764	7
	T	42	6,897	11	493	884	ND
	I	38	30,851	NA	431	1646	7
	U	37	16,212	6	360	578	ND
	K	36	448,343	NA	349	2445	7
	V	41	17,090	11	331	1067	ND
	J	53	74,199	NA	330	1397	7
W	46	32,236	11	277	1207	ND	
X	40	15,534	15	170	1133	ND	
Y	60	222,000	17	78	586	ND	
Z	47	467,160	21	66	1281	ND	

ND not determined; NA not available

Median CD8 count:

HIV-negative subjects:

**334** CD8 T cells/ $\mu$ l; range 246 – 563)



versus

HIV-infected subjects:

**1175** CD8 T cells/ $\mu$ l; range 578-3388)






( $p < 0.002$  HIV-negative versus HIV-infected)

# Gating Strategy for Analysis & Sorting



# T<sub>CM</sub> Cells Are Lost with Decreasing CD4 Counts

HIV-  
neg.



CD4  
count:

973






431

349

170

66

HIV+



VL: 8,278

30,851

448,343


15,534

467,160

CD28

CCR7







# Decreased Numbers of CD8<sup>+</sup> T<sub>CM</sub> cells / μl of Blood Correlate with Decreasing CD4 Counts



# Label Die-away Curves of CD8<sup>+</sup> T Cell Subpopulations

- HIV- (64 yr)
- ▲ HIV- (59 yr)
- ▼ HIV- (56 yr)
- ◆ HIV- (27 yr)







- ◇ HIV+ (VL 2K)
- △ HIV+ (VL 74K)
- ▽ HIV+ (VL 2K)
- HIV+ (VL 448K)
- HIV+ (VL 30K)



# $^2\text{H}$ Enrichment in CD8<sup>+</sup> T Cell Subpopulations

- HIV- (64 yr)
- ▲ HIV- (59 yr)
- ▼ HIV- (56 yr)
- ◆ HIV- (27 yr)

- ◇ HIV+ (VL 2K)
- △ HIV+ (VL 74K)
- ▽ HIV+ (VL 2K)
- HIV+ (VL 448K)
- HIV+ (VL 30K)





# Shorter Half-life of CD8<sup>+</sup> T<sub>CM</sub> Cells in HIV-infected Subjects with High Viral Load

CD3 <sup>+</sup> CD8 <sup>+</sup> T cell subset	Group	HIV copies/ml (log <sub>10</sub> )	k (decay constant)	T <sub>1/2</sub> (half-life in days)	Percentage of cells remaining	Cells/ul	% of CD3 <sup>+</sup> CD8 <sup>+</sup> T cells
<b>CD45RA<sup>-</sup>CCR7<sup>-</sup>CD28<sup>-</sup> (T<sub>EM2</sub>)</b>							
	HIV-negative	-	0.0119	58.1	51.3	8.3 (± 8.7)	2.2 (± 1.9)
	HIV-infected	4.3 (± 1.0)	0.0154 (± 0.0047)	49.3 (± 19.3)	43.3 (± 12.2)	241.4 (± 208.5)	9.9 (± 5.6)*
<b>CD45RA<sup>+</sup>CCR7<sup>-</sup>CD28<sup>-</sup> (T<sub>EMRA</sub>)</b>							
	HIV-negative	-	0.00007	9762	<b>99.6</b>	33.2 (± 27.3)	8.9 (± 6.4)
	HIV-infected	4.3 (± 1.0)	0.0069 (± 0.0028)	114.5 (± 47.2)	<b>68.5</b> (± 10.6)	515.9 (± 162.3)***	25.0 (± 5.3)**
<b>CD45RA<sup>-</sup>CCR7<sup>+</sup>CD28<sup>+</sup> (T<sub>CM</sub>)</b>							
	HIV-negative	-	<b>0.0079</b> (± 0.0029)	<b>97.7</b> (± 36.8)	<b>64.9</b> (± 10.4)	30.5 (± 21.7)	9.15 (± 7.5)
	HIV-infected	4.3 (± 1.0)	<b>0.0166</b> (± 0.0087) <sup>A</sup>	<b>51.0</b> (± 30.4) <sup>A</sup>	<b>45.5</b> (± 27.9) <sup>A</sup>	96.7 (± 60.6)	4.38 (± 1.2)
	HIV+ High VL	5.0 (± 0.6)	<b>0.0240</b> (± 0.0006) <sup>A</sup>	<b>28.8</b> (± 0.7) <sup>A</sup>	<b>26.0</b> (± 0.8) <sup>A</sup>	66.1 (± 12.4)	3.8 (± 1.1)
<b>CD45RA<sup>+</sup>CCR7<sup>+</sup>CD28<sup>+</sup> (T<sub>N</sub>)</b>							
	HIV-negative	-	-	-	175.5 (± 16.1)	159.4 (± 82)	44.0 (± 18.6)
	HIV-infected	4.3 (± 1.0)	-	-	42.8 (± 52.0)**	294.7 (± 198.9)	15.3 (± 11.6)

\* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001 HIV-negative versus HIV-infected;  
<sup>A</sup> p < 0.05 HIV-negative versus HIV-infected high VL

# Lower Percentages of CD8+ T<sub>CM</sub> Cells Remaining Correlate with Higher HIV VL



- HIV-infected
- HIV-negative



# Summary

- The different kinetic die-away patterns in different CD8<sup>+</sup> T cell subpopulations demonstrate that the turnover of low-abundance T cell subpopulations can now be studied using the refined stable isotope / FACS / mass spectrometric method.
- Two long-lived CD8<sup>+</sup> memory/effector T cell subpopulations were found: T<sub>CM</sub> cells expressing IL-7R $\alpha$  and T<sub>EMRA</sub> cells, of which a high fraction expresses CD57.
- T<sub>CM</sub> cells appear to have a shorter half-life in HIV-infected subjects than HIV-negative subjects and decline numerically with progressive HIV disease.
- T<sub>EMRA</sub> cells had a long half-life in both HIV-infected and HIV-negative subjects and were significantly increased in all HIV-infected subjects irrespective of their VL.

# Summary

- Accepted traits of hematopoietic stem cells (such as higher expression of the transcriptional repressor,  $bcl6b^*$ , or cell surface expression of  $IL-18R1\alpha^{**}$ ) could not be ascribed to these human  $CD8^+$  memory T cell subpopulations.
- However, a lower fraction of  $T_{CM}$  cells in HIV-infected individuals expressed  $IL-7R\alpha$  and the fraction of  $T_{CM}$  cells that expressed  $IL-7R\alpha$  trended to decrease with declining CD4 counts.
- The fraction of  $T_{EMRA}$  cells expressing  $IL-7R\alpha$ ,  $IL-18R\alpha$ , or  $CD57$  was also lower in HIV-infected individuals.

\* MandersPM. et al. PNAS (2005)

\*\* Luckey CJ. et al. PNAS (2006)

# Conclusions

- These data are consistent with the hypothesis that IL-7R $\alpha^+$  T<sub>CM</sub> cells represent “true” memory CD8<sup>+</sup> T cells, the loss of which may be responsible in part for the progressive loss of T cell memory function during progressive HIV infection.
- Further exploration of these observations may provide a more complete understanding of the manner in which the CD8<sup>+</sup> T cell compartment is eroded, both numerically and functionally, as HIV disease advances.

# Acknowledgements

## McCune Lab

Mike McCune

Paul Baum

Brinda Emu

David Favre

Joyce Trojano

Mary Beth Hanley

Diane Schmidt

## Positive Health Program

Steven Deeks

Rebecca Hoh

Marcia Smith, Joy Madamba, Regan Gage

Rick Hecht, Peter Hunt & Jason Barbour

## UC Berkeley

Marc Hellerstein

Drina Boban

Denise Cesar

Ben Hunrichs

Robert Busch

Richard Neese

Claire Emson

Bridget McEvoy-Hein

## THE STUDY PARTICIPANTS

## Gladstone Flow Core

Marty Bigos

Valerie Stepps

Tomasz Poplonski

## Immunology Core

Ck Poon

Elizabeth Sinclair

## Nixon Lab

Doug Nixon

Brian Long

Jennifer Snyder-

Cappione